Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug;41(8):2063-2068.
doi: 10.1007/s00345-022-04134-9. Epub 2022 Aug 30.

Current status and future perspectives of the managements of metastatic hormone-sensitive prostate cancer

Naoki Matsumura  1 , Kazutoshi Fujita  2 , Mitsuhisa Nishimoto  3 , Takafumi Minami  3 , Hideo Tahara  1 , Kazuhiro Yoshimura  3 , Hirotsugu Uemura  3
Affiliations
Review

Current status and future perspectives of the managements of metastatic hormone-sensitive prostate cancer

Naoki Matsumura et al. World J Urol. 2023 Aug.

Abstract

Purpose: The therapeutic landscape for metastatic hormone-sensitive prostate cancer (mHSPC) has changed dramatically. Here, we provide the current status and future prospective of the management of mHSPC.

Methods: We reviewed recent literature of landmark studies on the managements of mHSPC.

Results: Upfront docetaxel or androgen receptor signaling inhibitor (ARSi) in addition to ADT has improved survival in mHSPC patients and has become the new standard of care. Triplet therapy with docetaxel, ARSi and ADT also improved survival. In the future, triplet therapy may become the standard of care. Oligometastatic mHSPC patients could benefit from local therapy. The inclusion of risk factors or the genetic biomarkers will provide the best treatment for individual mHSPC patients.

Conclusion: Strong systemic therapy in the first-line treatment of mHSPC has been shown to improve survival and quality of life. Currently, several clinical trials are evaluating novel compounds such as PARP inhibitor, AKT inhibitor, and immune checkpoint inhibitor. The therapeutic landscape of mHSPC management will change dramatically.

Keywords: Abiraterone; Apalutamide; Darolutamide; Docetaxel; Enzalutamide; Metastatic hormone-sensitive prostate cancer.

PubMed Disclaimer

References

    1. Huggins C, Stevens RE Jr, Hodges CV (1941) Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43(2):209–223. https://doi.org/10.1001/archsurg.1941.01210140043004 - DOI
    1. Bubley GJ, Balk SP (1996) Treatment of androgen-independent prostate cancer. Oncologist 1(1):30–35. https://doi.org/10.1634/theoncologist.1-1-30 - DOI - PubMed
    1. Tangen CM, Hussain MH, Higano CS, Eisenberger MA, Small EJ, Wilding G et al (2012) Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol 188(4):1164–1169. https://doi.org/10.1016/j.juro.2012.06.046 - DOI - PubMed - PMC
    1. Labrie F, Dupont A, Belanger A, Cusan L, Lacourciere Y, Monfette G et al (1982) New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 5(4):267–275 - PubMed
    1. (2000) Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials Prostate Cancer Trialists’ Collaborative Group. Lancet. 355(9214):1491–1498 https://doi.org/10.1016/S0140-6736(00)02163-2

MeSH terms

LinkOut - more resources